Sentence: This phase 1 trial determined the safety , pharmacokinetics , and antitumor activity of LY3022855 in combination with durvalumab or tremelimumab in patients with advanced solid cancers who had received standard anti-cancer treatments .
Drug combination annotation:
[{'class': 'POS', 'spans': ['LY3022855', 'durvalumab'], 'is_context_needed': True}, {'class': 'POS', 'spans': [0, 2], 'is_context_needed': True}]